Fulcrum Asset Management LLP Purchases 46,568 Shares of Twist Bioscience Corporation $TWST

Fulcrum Asset Management LLP purchased a new position in Twist Bioscience Corporation (NASDAQ:TWST) in the 3rd quarter, Holdings Channel.com reports. The fund purchased 46,568 shares of the company’s stock, valued at approximately $8,668,000.

Several other institutional investors have also added to or reduced their stakes in the business. E. Ohman J or Asset Management AB purchased a new position in shares of Twist Bioscience in the second quarter worth about $853,000. Allspring Global Investments Holdings LLC bought a new stake in shares of Twist Bioscience in the 1st quarter valued at about $22,563,000. Bank of America Corp DE boosted its holdings in Twist Bioscience by 46.3% during the 1st quarter. Bank of America Corp DE now owns 584,261 shares of the company’s stock valued at $27,764,000 after acquiring an additional 184,907 shares during the period. The Manufacturers Life Insurance Company purchased a new position in Twist Bioscience in the 2nd quarter worth approximately $8,215,000. Finally, William Blair Investment Management LLC purchased a new position in Twist Bioscience in the 2nd quarter worth approximately $223,722,000.

Twist Bioscience Stock Performance

TWST opened at $120.79 on Monday. The company has a quick ratio of 2.38, a current ratio of 2.67 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a 52 week low of $23.30 and a 52 week high of $219.71. The stock has a market cap of $7.57 billion, a PE ratio of -54.41 and a beta of 2.25. The business has a 50 day moving average of $151.35 and a 200-day moving average of $91.08.

Insider Activity

In other Twist Bioscience news, CFO Adam Laponis sold 8,057 shares of the stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $188.88, for a total transaction of $1,521,806.16. Following the sale, the chief financial officer directly owned 100,576 shares in the company, valued at approximately $18,996,794.88. This trade represents a 7.42% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Emily Leproust sold 356,546 shares of Twist Bioscience stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $157.99, for a total value of $56,330,702.54. Following the completion of the sale, the chief executive officer directly owned 620,589 shares of the company’s stock, valued at approximately $98,046,856.11. The trade was a 36.49% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 495,279 shares of company stock valued at $80,489,387 in the last quarter. Insiders own 3.08% of the company’s stock.

Analyst Ratings Changes

Several analysts have weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Twist Bioscience in a research report on Monday, September 21st. Guggenheim raised their target price on shares of Twist Bioscience from $107.00 to $212.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. Jefferies Financial Group initiated coverage on shares of Twist Bioscience in a research note on Thursday, October 8th. They issued a “hold” rating and a $150.00 target price on the stock. BWS Financial reiterated a “sell” rating and set a $45.00 price target on shares of Twist Bioscience in a report on Friday, September 18th. Finally, TD Cowen upped their price target on shares of Twist Bioscience from $115.00 to $190.00 and gave the company a “buy” rating in a report on Tuesday, October 13th. Seven investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $153.00.

Key Stories Impacting Twist Bioscience

Here are the key news stories impacting Twist Bioscience this week:

• Positive Sentiment: Twist launched MRD Express, potentially expanding its presence in minimal residual disease testing. Investors may look for further details on the product and business outlook around earnings. Article: Twist Bioscience stock enters earnings week after MRD Express launch
• Neutral Sentiment: CEO Emily Leproust and three other insiders sold a combined 6,677 shares at $135.40. The sales were disclosed as covering tax withholding on equity-award vesting, and each seller retained a substantial stake.
• Negative Sentiment: Shares fell amid a negative report from The Bear Cave/Hunterbrook. The provided article headline does not specify the report’s allegations, but its release appears to have hurt sentiment. Article: Twist Bioscience falls amid negative report

About Twist Bioscience

Twist Bioscience Corporation is a biotechnology company that uses a silicon-based platform to manufacture synthetic DNA. Its technology supports the production of many DNA sequences in parallel for research and commercial applications.

The company provides synthetic genes, gene fragments and oligonucleotide pools, as well as tools for next-generation sequencing, including target-enrichment products. Through its biopharma business, Twist also offers antibody discovery and related services to support the development of therapeutics.

Founded in 2013 and headquartered in South San Francisco, California, Twist serves customers in biotechnology, pharmaceutical, academic, agricultural and other industries around the world.